Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery (PCP002)
|ClinicalTrials.gov Identifier: NCT02225353|
Recruitment Status : Completed
First Posted : August 26, 2014
Results First Posted : October 23, 2018
Last Update Posted : October 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Preterm Birth||Drug: Progesterone Cervical Pessary 6.3 g Drug: Progesterone 200 mg vaginal capsules Drug: Progesterone Cervical Pessary 7.7 g||Phase 2|
Participant selection will be performed by screening the general population of pregnant women with single fetus monitored by the Hospital Healthcare Network, to investigate by serial transvaginal ultrasound performed between gestation weeks 16 (0 day to 7 days) and 24 (0 day to 7 days) those patients who have a cervical length between 10 mm and 25 mm, and/or women with a single fetus and cervical length ≥10 mm presenting one or more of the following risk factors:
- preterm birth prior to 35 (34 weeks and 6 days) weeks of gestation;
- premature rupture of membranes prior to 35 (34 and 6 days) weeks of gestation.
After insertion of the pessary or beginning of the administration with vaginal progesterone capsules and until 28 weeks of gestation, participants in the 3 treatment groups will be monitored every 4 weeks at the most or more often, if the site has established so as a control standard. After 28 weeks, patients should be monitored every 2 weeks.
The proportions of spontaneous preterm delivery before gestation weeks 32 and 34 will be compared between the control group and the 2 groups with the pessaries containing different doses of progesterone.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||271 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-Label, Controlled, Multi-Center Study on the Efficacy of a Sustained Release Progesterone Cerclage Cervical Pessary at Doses of 6.3 g or 7.7 g for the Prevention of Preterm Birth and a Maximum Duration of 20 Weeks.|
|Actual Study Start Date :||September 2, 2013|
|Actual Primary Completion Date :||March 13, 2017|
|Actual Study Completion Date :||March 13, 2017|
Experimental: Progesterone Cervical Pessary 6.3 g
90 pregnant women with Progesterone Cervical Pessary
Drug: Progesterone Cervical Pessary 6.3 g
Progesterone Cervical Pessary low dose
Experimental: Progesterone Cervical Pessary 7.7 g
90 pregnant women with Progesterone Cervical Pessary
Drug: Progesterone Cervical Pessary 7.7 g
Progesterone Cervical Pessary high dose
Active Comparator: Progesterone 200 mg vaginal capsules
90 pregnant women using Progesterone 200 mg vaginal capsules daily
Drug: Progesterone 200 mg vaginal capsules
Progesterone 200 mg vaginal capsules daily
Other Name: Hormoral (Trade Mark) Capsules
- Number of Participants Not Giving Birth Before Week 32 and Week 34 of Gestation [ Time Frame: Up to 36 weeks of gestational age ]
To assess the efficacy of Cerclage Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous parturition before gestation weeks 32 (31 weeks and 6 days) and 34 (33 weeks and 6 days), when the pessary is inserted between weeks 16 and 24 and removed at 36 weeks and 6 days in pregnant women at high risk of premature delivery.
For the purpose of this analysis, pregnancies were no longer considered as high risk for the event if delivery occurred at week 34 of gestation and beyond. Gestational age was determined by the last menstruation date and were confirmed by measurement of the craniocaudal length obtained in the first trimester ultrasound, or by measurement of the cephalic circumference in the second trimester ultrasound predominating the actual date of the last menstrual period.
The number of participants not giving birth before 32 weeks and 34 weeks are reported.
- Number of Participants With Premature Rupture of Membranes [ Time Frame: Up to 36 weeks of gestational age ]A participant with premature rupture of membrane typically recalls a sudden gush of fluid loss from the vagina, or steady loss of small amounts of fluid. Participants who reported vaginal discharge were examined by a physician.
- Anatomical Feature: Length of the Uterine Cervix [ Time Frame: Up to 36 weeks of gestational age. Results are reported for all assessments from baseline through final visit, for a total of 8 visits, and for up to 36 weeks of gestational age. ]During the pregnancy the length of the uterine cervix will be assessed. The rational is that premature birth is associated with uterine cervix shortening. The length of the cervix was determined using ultrasound examination. A positive change from baseline indicates a positive development, i.e. less likely to result in a preterm birth. The comparison between premature an normal birth initially planned by the protocol was not analyzed.
- Anatomical Feature: Position of the Uterine Cervix [ Time Frame: Up to 36 weeks of gestational age. Results are reported for all assessments from baseline through final visit, for a total of 8 visits, and for up to 36 weeks of gestational age. ]During the pregnancy the position of the uterine cervix will be assessed. The rational being that premature birth is associated with uterine cervix positioning. The position of the cervix was determined using transvaginal ultrasound examination. In the change from baseline visit a positive value change indicated that the investigator believed that the position of the cervix changed in a positive manner to facilitate a term birth. The comparison between premature an normal birth initially planned by the protocol was not analyzed. The results reported are the degrees of the cervix position relative to the longitudinal axis of the uterus.
- Acceptability and Tolerance of Use of the Cerclage Pessary [ Time Frame: Up to 36 weeks of gestational age ]
A questionnaire was planned to be used to compare acceptability and tolerance in the insertion, during pregnancy and during the extraction of Cerclage Pessary.
Data from this questionnaire was not collected.
- Number of Adverse Events Related With the Use of Treatment [ Time Frame: Up to 36 weeks of gestational age ]The number of adverse events reported were analyzed as being related with the treatment as well as for unexpectedness.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02225353
|Universidad de Chile, Hospital Barros Luco|
|Santiago, Chile, 7501257|
|Complejo Asistencial Dr. Sótero del Río (CASR)|
|Unidad de Alto Riesgo Obstétrico y Medicina Perinatal y en el Centro Perinatal Oriente (CERPO), Hospital Santiago Oriente, Dr. Luis Tisné Brousse|
|Universidad de Chile, Hospital Clínico San Borja Arriarán|
|Study Director:||Grünenthal Study Director||Grünenthal GmbH|